🚀 VC round data is live in beta, check it out!
Kiniksa Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kiniksa Pharmaceuticals and similar public comparables like TransThera Sciences, Aspen Pharmacare, Edgewise Therapeutics, Kangmei Pharmaceutical Co. and more.
Kiniksa Pharmaceuticals Overview
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Founded
2015
HQ
Employees
315
Website
Sectors
Financials (LTM)
EV
$3B
Kiniksa Pharmaceuticals Financials
Kiniksa Pharmaceuticals reported last 12-month revenue of $742M and EBITDA of $108M.
In the same LTM period, Kiniksa Pharmaceuticals generated $657M in gross profit, $108M in EBITDA, and $69M in net income.
Revenue (LTM)
Kiniksa Pharmaceuticals P&L
In the most recent fiscal year, Kiniksa Pharmaceuticals reported revenue of $678M and EBITDA of $90M.
Kiniksa Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $742M | XXX | $678M | XXX | XXX | XXX |
| Gross Profit | $657M | XXX | $370M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $108M | XXX | $90M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 13% | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $69M | XXX | $59M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 9% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kiniksa Pharmaceuticals Stock Performance
Kiniksa Pharmaceuticals has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Kiniksa Pharmaceuticals' stock price is $47.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | 0.6% | XXX | XXX | XXX | $0.77 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKiniksa Pharmaceuticals Valuation Multiples
Kiniksa Pharmaceuticals trades at 4.3x EV/Revenue multiple, and 29.8x EV/EBITDA.
EV / Revenue (LTM)
Kiniksa Pharmaceuticals Financial Valuation Multiples
As of April 10, 2026, Kiniksa Pharmaceuticals has market cap of $4B and EV of $3B.
Equity research analysts estimate Kiniksa Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kiniksa Pharmaceuticals has a P/E ratio of 52.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBITDA | 29.8x | XXX | 35.6x | XXX | XXX | XXX |
| EV/EBIT | 33.7x | XXX | 39.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | 8.7x | XXX | XXX | XXX |
| P/E | 52.2x | XXX | 61.4x | XXX | XXX | XXX |
| EV/FCF | 411.5x | XXX | 23.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kiniksa Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kiniksa Pharmaceuticals Margins & Growth Rates
Kiniksa Pharmaceuticals' revenue in the last 12 month grew by 29%.
Kiniksa Pharmaceuticals' revenue per employee in the last FY averaged $2.2M, while opex per employee averaged $0.9M for the same period.
Kiniksa Pharmaceuticals' rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kiniksa Pharmaceuticals' rule of X is 104% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Kiniksa Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 29% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 58% | XXX | 71% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 104% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kiniksa Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| TransThera Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Aspen Pharmacare | XXX | XXX | XXX | XXX | XXX | XXX |
| Edgewise Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kangmei Pharmaceutical Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Liquidia | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kiniksa Pharmaceuticals M&A Activity
Kiniksa Pharmaceuticals acquired XXX companies to date.
Last acquisition by Kiniksa Pharmaceuticals was on XXXXXXXX, XXXXX. Kiniksa Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kiniksa Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKiniksa Pharmaceuticals Investment Activity
Kiniksa Pharmaceuticals invested in XXX companies to date.
Kiniksa Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Kiniksa Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kiniksa Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kiniksa Pharmaceuticals
| When was Kiniksa Pharmaceuticals founded? | Kiniksa Pharmaceuticals was founded in 2015. |
| Where is Kiniksa Pharmaceuticals headquartered? | Kiniksa Pharmaceuticals is headquartered in United States. |
| How many employees does Kiniksa Pharmaceuticals have? | As of today, Kiniksa Pharmaceuticals has over 315 employees. |
| Who is the CEO of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals' CEO is Sanj K. Patel. |
| Is Kiniksa Pharmaceuticals publicly listed? | Yes, Kiniksa Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals trades under KNSA ticker. |
| When did Kiniksa Pharmaceuticals go public? | Kiniksa Pharmaceuticals went public in 2018. |
| Who are competitors of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals main competitors are TransThera Sciences, Aspen Pharmacare, Edgewise Therapeutics, Kangmei Pharmaceutical Co.. |
| What is the current market cap of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals' current market cap is $4B. |
| What is the current revenue of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals' last 12 months revenue is $742M. |
| What is the current revenue growth of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals revenue growth (NTM/LTM) is 29%. |
| What is the current EV/Revenue multiple of Kiniksa Pharmaceuticals? | Current revenue multiple of Kiniksa Pharmaceuticals is 4.3x. |
| Is Kiniksa Pharmaceuticals profitable? | Yes, Kiniksa Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals' last 12 months EBITDA is $108M. |
| What is Kiniksa Pharmaceuticals' EBITDA margin? | Kiniksa Pharmaceuticals' last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Kiniksa Pharmaceuticals? | Current EBITDA multiple of Kiniksa Pharmaceuticals is 29.8x. |
| What is the current FCF of Kiniksa Pharmaceuticals? | Kiniksa Pharmaceuticals' last 12 months FCF is $8M. |
| What is Kiniksa Pharmaceuticals' FCF margin? | Kiniksa Pharmaceuticals' last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Kiniksa Pharmaceuticals? | Current FCF multiple of Kiniksa Pharmaceuticals is 411.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.